Antimetabolites in ocular surface neoplasia.
Malignant neoplasms of the ocular surface are uncommon but consist of squamous and melanocytic tumors. Surgical excision has been the mainstay of treatment and is perhaps the "gold standard." However, in those circumstances in which surgical intervention is not feasible, adjunctive treatments have been advocated. Recent attention has been given to the use of mitomycin C and 5-fluorouracil for the treatment of ocular surface squamous neoplasia. This article reviews the major publications relating to the use of antimetabolites in ocular surface neoplasia and highlights the most recent contributions to the ophthalmic literature.
Majmudar
P A
PA
Department of Ophthalmology, Cornea Service, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.
Epstein
R J
RJ
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009883:Ophthalmic Solutions; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D009883:Ophthalmic Solutions